Calithera Biosciences Inc
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Calithera Biosciences Inc (CALA) - Net Assets
Latest net assets as of December 2022: $20.39 Million USD
Based on the latest financial reports, Calithera Biosciences Inc (CALA) has net assets worth $20.39 Million USD as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.68 Million) and total liabilities ($8.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.39 Million |
| % of Total Assets | 71.11% |
| Annual Growth Rate | N/A |
| 5-Year Change | -83.91% |
| 10-Year Change | N/A |
| Growth Volatility | 92.92 |
Calithera Biosciences Inc - Net Assets Trend (2012–2022)
This chart illustrates how Calithera Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Calithera Biosciences Inc (2012–2022)
The table below shows the annual net assets of Calithera Biosciences Inc from 2012 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $20.39 Million | +143.28% |
| 2021-12-31 | $8.38 Million | -91.81% |
| 2020-12-31 | $102.37 Million | -28.12% |
| 2019-12-31 | $142.43 Million | +12.40% |
| 2018-12-31 | $126.71 Million | -15.70% |
| 2017-12-31 | $150.31 Million | +201.18% |
| 2016-12-31 | $49.91 Million | -30.48% |
| 2015-12-31 | $71.79 Million | -28.47% |
| 2014-12-31 | $100.37 Million | +582.23% |
| 2013-12-31 | $-20.81 Million | -142.83% |
| 2012-12-31 | $-8.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Calithera Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 49485100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $533.01 Million | 2613.81% |
| Total Equity | $20.39 Million | 100.00% |
Calithera Biosciences Inc Competitors by Market Cap
The table below lists competitors of Calithera Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PACIFIC ONLINE
BE:4P7
|
$1.46K |
|
Ccs
WAR:CCS
|
$1.46K |
|
SINOPEC SH PETRO-H- - Dusseldorf Stock Exchang
DU:SGJH
|
$1.46K |
|
Blackrock Smaller Companies Trust PLC
LSE:BRSC
|
$1.46K |
|
Da Nang Construction Building Materials Vicem JSC
VN:DXV
|
$1.46K |
|
Prosperity Weaving Mills Ltd
KAR:PRWM
|
$1.46K |
|
MCB INDIA SOVEREIGN BOND (FIXED INCOME)-(USD)
SEM:MISB
|
$1.46K |
|
CREO MEDICAL GRP LS-001
F:1RC
|
$1.46K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Calithera Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 8,382,000 to 20,392,000, a change of 12,010,000 (143.3%).
- Net loss of 18,866,000 reduced equity.
- New share issuances of 9,639,000 increased equity.
- Other comprehensive income increased equity by 40,702,000.
- Other factors decreased equity by 19,465,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.87 Million | -92.52% |
| Share Issuances | $9.64 Million | +47.27% |
| Other Comprehensive Income | $40.70 Million | +199.6% |
| Other Changes | $-19.46 Million | -95.45% |
| Total Change | $- | 143.28% |
Book Value vs Market Value Analysis
This analysis compares Calithera Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-21.72 | $0.00 | x |
| 2013-12-31 | $-52.73 | $0.00 | x |
| 2014-12-31 | $-222.93 | $0.00 | x |
| 2015-12-31 | $79.57 | $0.00 | x |
| 2016-12-31 | $51.22 | $0.00 | x |
| 2017-12-31 | $91.23 | $0.00 | x |
| 2018-12-31 | $69.24 | $0.00 | x |
| 2019-12-31 | $60.21 | $0.00 | x |
| 2020-12-31 | $29.75 | $0.00 | x |
| 2021-12-31 | $2.27 | $0.00 | x |
| 2022-12-31 | $4.08 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Calithera Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -92.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.41x
- Recent ROE (-92.52%) is above the historical average (-163.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.12 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.30 Million |
| 2014 | 0.00% | -241244.44% | 0.00x | 0.00x | $-16.53 Million |
| 2015 | -45.47% | 0.00% | 0.00x | 1.06x | $-39.82 Million |
| 2016 | -76.15% | 0.00% | 0.00x | 1.10x | $-42.99 Million |
| 2017 | -18.51% | -107.21% | 0.13x | 1.28x | $-42.86 Million |
| 2018 | -40.62% | -231.29% | 0.16x | 1.13x | $-64.14 Million |
| 2019 | -60.63% | 0.00% | 0.00x | 1.18x | $-100.59 Million |
| 2020 | -86.47% | 0.00% | 0.00x | 1.23x | $-98.76 Million |
| 2021 | -1373.04% | -1180.39% | 0.15x | 7.73x | $-115.93 Million |
| 2022 | -92.52% | 0.00% | 0.00x | 1.41x | $-20.91 Million |
Industry Comparison
This section compares Calithera Biosciences Inc's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Calithera Biosciences Inc (CALA) | $20.39 Million | 0.00% | 0.41x | $1.46K |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |